Trial Profile
Phase I trial of GRC 17536.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2011
Price :
$35
*
At a glance
- Drugs ISC 17536 (Primary)
- Indications Pain; Respiratory tract disorders
- Focus Adverse reactions
- Sponsors Glenmark Pharmaceuticals Ltd
- 17 Feb 2011 Glenmark reports that the trial is expected to be initiated in the Netherlands in the near future.
- 17 Feb 2011 Planned End Date is 1 Dec 2011.
- 30 Aug 2010 Glenmark plans to file the Phase 1 application in January 2011, according to a media release.